Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer

Peter Fritz, Cristina M Cabrera, Jürgen Dippon, Andreas Gerteis, Wolfgang Simon, Walter E Aulitzky, Heiko van der Kuip, c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective study Breast Cancer Research. ,vol. 7, pp. 1- 11 ,(2005) , 10.1186/BCR1012

A.-M. C. Dingemans, P. Van Der Valk, M. A. Witlox, R. A. L. M. Stallaert, G. Giaccone, P. E. Postmus, Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer Clinical Cancer Research. ,vol. 5, pp. 2048- 2058 ,(1999)

Jacek Jassem, Tadeusz Pieńkowski, Anna Płuzańska, Svetislav Jelic, Vera Gorbunova, Zrinka Mrsic-Krmpotic, Juris Berzins, Tomas Nagykalnai, Nelly Wigler, Josette Renard, Stephane Munier, Catherine Weil, Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial Journal of Clinical Oncology. ,vol. 19, pp. 1707- 1715 ,(2001) , 10.1200/JCO.2001.19.6.1707

Satoshi Oizumi, , Koichi Yamazaki, Hiroshi Yokouchi, Jun Konishi, Fumihiro Hommura, Tetsuya Kojima, Hiroshi Isobe, Masaharu Nishimura, Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy International Journal of Clinical Oncology. ,vol. 14, pp. 125- 129 ,(2009) , 10.1007/S10147-008-0808-9

Mitsuharu Hanada, Toshihiro Noguchi, Takashi Yamaoka, Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo Cancer Science. ,vol. 98, pp. 447- 454 ,(2007) , 10.1111/J.1349-7006.2007.00404.X

N. Tani, M. Yabuki, S. Komuro, H. Kanamaru, Characterization of the enzymes involved in thein vitrometabolism of amrubicin hydrochloride Xenobiotica. ,vol. 35, pp. 1121- 1133 ,(2005) , 10.1080/00498250500342746

Shuji Murakami, Fumihiro Oshita, Makiko Sugiura, Tetsuro Kondo, Haruhiro Saito, Kouzo Yamada, Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. Cancer Chemotherapy and Pharmacology. ,vol. 71, pp. 705- 711 ,(2013) , 10.1007/S00280-012-2061-1

Koji Takeda, Nobuhide Takifuji, Shunichi Negoro, Kiyoyuki Furuse, Shinichiro Nakamura, Yoshiki Takada, Takanobu Hoso, Shinichi Hayasaka, Takashi Nakano, Jun Araki, Hiroshi Senba, Fumiyuki Iwami, Yasufumi Yamaji, Masahiro Fukuoka, Harumichi Ikegami, Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study Investigational New Drugs. ,vol. 25, pp. 377- 383 ,(2007) , 10.1007/S10637-007-9039-6

Naoyuki Nogami, Katsuyuki Hotta, Yoshihiko Segawa, Nagio Takigawa, Shinobu Hosokawa, Isao Oze, Masanori Fujii, Eiki Ichihara, Takuo Shibayama, Atsuhiko Tada, Noboru Hamada, Masatoshi Uno, Akihiko Tamaoki, Shoichi Kuyama, Genyo Ikeda, Masahiro Osawa, Saburo Takata, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura, Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402. Acta Oncologica. ,vol. 51, pp. 768- 773 ,(2012) , 10.3109/0284186X.2011.648342

K Shimizu, K Kaira, Y Tomizawa, N Sunaga, O Kawashima, N Oriuchi, H Tominaga, S Nagamori, Y Kanai, M Yamada, T Oyama, I Takeyoshi, ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. British Journal of Cancer. ,vol. 110, pp. 2030- 2039 ,(2014) , 10.1038/BJC.2014.88